Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets

The American Journal of Surgical Pathology
Christina MitteldorfWerner Kempf

Abstract

Programmed death ligand 1 (PD-L1) is expressed by 20% to 57% of systemic diffuse large B cell lymphomas (DLBCLs). PD-L1 expression in primary cutaneous DLBCL (pcDLBCL) has not been studied so far. Sixteen paraffin-embedded tissue samples of pcDLBCL (13 leg type [LT], 3 others [OT]) were investigated for PD-1, PD-L1, and CD33 expression and the cellular composition of the tumor microenvironment, focusing on myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages. Membrane-bound PD-L1 expression by the tumor cells was observed in all samples, albeit to a variable extent (19.9%). As expected, most DLBCL-LT (10 cases) were classified as activated B cell like type, with a higher PD-L1 score (21.9%) compared with that of the germinal center B cell like type (7.7%). The surrounding infiltrate consisted predominately of CD163(+) M2 rather than CD68(+) macrophages (CD68:CD163=1:4 to 6). Moreover, a considerable proportion of CD33(+) MDSCs with PD-L1 coexpression was admixed. Tumor cells expressed CD33 to variable degrees (2% to 60%). The number of MDSCs or M2 macrophages did not correlate with pcDLBCL subtypes LT or OT. T cells were only a minor component of the tumor microenvironment. We propose that PD-L1(+) tumor ce...Continue Reading

References

Sep 13, 2001·Journal of Cutaneous Pathology·J KamarashevW Kempf
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun KonishiMasaharu Nishimura
Feb 5, 2005·Blood·Rein WillemzeChris J L M Meijer
Apr 12, 2006·The Journal of Experimental Medicine·Ilona KryczekWeiping Zou
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·R Houston ThompsonEugene D Kwon
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takeo NomiYoshiyuki Nakajima
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas F Gajewski
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Jan 29, 2008·Blood·Takeshi AzumaLieping Chen
Mar 22, 2008·The Journal of Urology·Jonathan C RouthEugene D Kwon
May 10, 2008·Seminars in Cancer Biology·Antonio SicaAlberto Mantovani
Nov 29, 2008·The New England Journal of Medicine·G LenzUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Oct 1, 2009·Expert Reviews in Molecular Medicine·John C Morris, Thomas A Waldmann
Jan 18, 2011·International Immunopharmacology·Tim F GretenFirouzeh Korangy
Apr 9, 2011·Cancer Biology & Therapy·Michael R ShurinGalina V Shurin
May 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J AndorskyJohn M Timmerman
Nov 29, 2011·Cancer Immunology, Immunotherapy : CII·Paola FilipazziLicia Rivoltini
Mar 23, 2012·Nature Reviews. Immunology·Dmitry I GabrilovichVincenzo Bronte
Aug 4, 2012·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Isabel Poschke, Rolf Kiessling
Feb 20, 2013·The Journal of Investigative Dermatology·Mitra DowlatshahiRachael A Clark
May 16, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin J ChenScott J Rodig
Aug 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Olga K AfanasievPaul Nghiem
Sep 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mario Sznol, Lieping Chen
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Dec 11, 2014·Expert Opinion on Therapeutic Targets·Simone MuenstSylvia Hoeller
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Aug 13, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·W HuC Wu
Oct 5, 2015·Dermatologic Clinics·Werner Kempf, Christina Mitteldorf
Apr 1, 2016·Blood·Konstantinos GeorgiouQiang Pan-Hammarström

❮ Previous
Next ❯

Citations

Mar 28, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sarah MenguyAnne Pham-Ledard
Mar 10, 2019·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Moritz FelchtWerner Kempf
Mar 29, 2019·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Moritz FelchtWerner Kempf
Mar 5, 2020·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Christina Mitteldorf
Mar 21, 2020·Medicine·Qi WangYisheng Tao
Apr 21, 2020·Journal of Cutaneous Pathology·Beatrice JoestChristina Mitteldorf
Dec 5, 2019·Frontiers in Oncology·Giulia Tadiotto CicognaMauro Alaibac
Jan 12, 2021·Human Vaccines & Immunotherapeutics·Chen ChenBinbin Cui
Aug 14, 2019·Clinical Oncology : a Journal of the Royal College of Radiologists·L Specht, L Skov
Jun 29, 2021·Frontiers in Oncology·Qianhui GuSong He

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.